查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371922

到 2030 年骨髓移植市场预测：按移植类型、适应症、最终用户和地区进行的全球分析

Bone Marrow Transplant Market Forecasts to 2030 - Global Analysis By Transplant Type, Disease Indication, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球骨髓移植市场规模为106.5亿美元，预计2030年将达到153.9亿美元，预测期内年复合成长率为5.4%。

长骨内部有称为骨髓的软骨组织。有两种类型：造血干细胞和间质干细胞。骨髓的主要功能是造血、淋巴球生成和脂肪储存。此外，骨髓移植（BMT）是治疗某些癌症（如白血病和淋巴瘤）患者的独特治疗方法。干细胞通常存在于骨髓中，在骨髓移植过程中取出、过滤，然后回到捐赠者（病人）或另一个人体内。

根据致力于根除癌症的志愿组织美国癌症协会 2022 年 1 月提供的资料，非何杰金氏淋巴瘤(NHL) 是美国最常见的癌症之一，占所有癌症的大多数。约占4%。

血液疾病增加

白血病、淋巴瘤和多发性骨髓瘤等血液疾病在世界上变得越来越常见。环境暴露、生活方式的改变和高龄化都会产生影响。此外，诊断和早期检测技术的改进使更多病例更早检测，并增加了人们对骨髓移植作为潜在治疗和治癒方法的兴趣。此外，由于标靶治疗和精准医疗技术的发展，可以从移植中受益的患者数量不断增加，这些技术可以与移植相结合以改善治疗效果。

昂贵的移植费用

骨髓移植市场的主要障碍之一是移植成本高。移植前评估、预处理方案、实际移植、移植后照护和长期追踪都是昂贵的程序。对于许多患者来说，即使在医疗保健系统高度发展的地区，这些费用也可能成为治疗的障碍。此外，保险并不总是涵盖全部费用，这给患者带来了沉重的财务负担。

个人化医疗的现代化

骨髓移植领域受到基因组和分子分析驱动的个人化医疗的极大影响。透过根据个人的遗传和分子特征量身订做移植策略和移植后治疗，可以改善移植结果并减少併发症。此外，该策略减少了副作用，同时提高了移植的整体疗效。

医疗费用和财务限制

骨髓移植对病患和医疗保健系统带来的巨大经济负担是骨髓移植市场的主要威胁之一。移植前评估、预处理方案、实际移植、移植后护理和长期追踪的高昂费用可能导致许多患者选择不接受移植。此外，高昂的医疗费用可能会对保险系统造成压力，并阻止服务不足的人口接受移植手术。

COVID-19 的影响：

COVID-19大流行对骨髓移植市场产生了重大影响。全球医疗保健系统受到疫情影响，非紧急移植手术被推迟或取消，以节省医疗资源并降低弱势患者的感染风险。然而，人们对移植受者免疫力缺乏功能低下状况的担忧日益增加，需要采取严格的感染控制措施并修改移植方案。

预计在预测期内，白血病领域将是最大的。

白血病在骨髓移植市场中占据最大的市场占有率。骨髓移植最常见且众所周知的原因之一是白血病，其特征是白血球异常增生。各种类型白血病的高患病，包括急性淋巴性白血病（ALL）、急性骨髓性白血病（AML）和慢性骨髓性白血病（CML），显着增加了移植服务的需求。此外，移植方法、支持治疗和标靶治疗的改进也提高了白血病患者的成功率，进一步推动了该市场的扩张。

预计门诊手术中心部门在预测期内年复合成长率最高

在骨髓移植市场中，门诊手术中心（ASC）领域维持最高的年复合成长率。 ASC 提供各种门诊外科手术，包括一些药物治疗和微创手术。 ASC 越来越受欢迎，因为它们提供负担得起且实用的医疗保健、住院时间短和感染风险低。此外，ASC 最近已扩展到提供各种服务，包括整形外科、眼科、胃肠病学、疼痛管理和许多其他领域。

比最大的地区

北美地区占据骨髓移植最大的市场占有率。这一优势得益于多种要素，包括强有力的法规环境、完善的医疗基础设施、需要骨髓移植的血液疾病的高患病以及尖端的医疗技术。此外，北美受益于广泛的研究和开发工作、高额医疗支出和庞大的捐助者库。该地区的市场领导地位也得益于患者和医疗保健提供者对骨髓移植益处的认识不断提高。

复合年复合成长率最高的地区：

骨髓移植市场年复合成长率最高的是中东和北非（MENA）地区。这一增长的推动因素包括医疗保健投资的增加、医疗保健基础设施的改善以及公众对骨髓移植等最先进治疗的认识的提高。此外，阿拉伯联合大公国、沙乌地阿拉伯和卡达等中东和北非国家显着改善了医疗基础设施，使其公民更容易接受骨髓移植。对移植服务的需求不断增长也是由于该地区血液疾病的患病不断上升，从而推动了市场的扩张。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球骨髓移植市场：依移植类型分类

  • 自体骨髓移植
  • 同种异体骨髓移植
  • 其他类型的移植

第6章全球骨髓移植市场：依疾病适应症

  • 白血病
  • 淋巴瘤
  • 骨髓瘤
  • 地中海型贫血
  • 骨髓发育不良症候群
  • 骨髓增生性疾病
  • 再生障碍性贫血
  • 固态肿瘤
  • 镰状细胞性贫血
  • 其他疾病的适应症

第7章全球骨髓移植市场：依最终用户分类

  • 医院
  • 多专科诊所
  • 门诊手术中心
  • 其他最终用户

第8章全球骨髓移植市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • Gamida Cell Ltd.
  • Mesoblast Ltd.
  • American Type Culture Collection（ATCC）Inc
  • Lonza Group Ltd.
  • FUJIFILM Cellular Dynamics, Inc.
  • ReachBio LLC.
  • Sanofi-Aventis LLC.
  • PromoCell GmbH
  • Abbott Laboratories Inc
  • The Emmes Company LLC
  • CORESTEM, Inc.
  • StemCell Technologies.
  • Hemacare Corporation
  • AllCells LLC.
  • Lifeline Cell Technology LLC
  • ReeLabs Pvt. Ltd.
  • Charles River Laboratories
  • Merck Millipore Corporation
Product Code: SMRC23979

According to Stratistics MRC, the Global Bone Marrow Transplant Market is accounted for $10.65 billion in 2023 and is expected to reach $15.39 billion by 2030 growing at a CAGR of 5.4% during the forecast period. In the interior of long bones, there is a soft vascular tissue called bone marrow. Hematopoietic and mesenchymal stem cells make up both types of stem cells. The main functions of bone marrow are hematopoiesis, lymphocyte production, and fat storage. Additionally, a unique form of treatment for people with certain cancers, such as leukemia, lymphoma, or other conditions, is bone marrow transplantation (BMT). Stem cells that are typically found in the bone marrow are removed during a bone marrow transplant, filtered, and then returned to the donor (patient) or to another individual.

According to data provided by the American Cancer Society, Inc., a voluntary health organization dedicated to eliminating cancer, in January 2022, Non-Hodgkin lymphoma (NHL) is one of the most common cancers in the U.S., accounting for about 4% of all cancers.

Market Dynamics:

Driver:

Increasing incidence of haematological disorders

Hematological disorders like leukemia, lymphoma, and multiple myeloma are becoming more commonplace in the world. Environmental exposures, alterations in lifestyle, and an aging population all play a role. Furthermore, as a result of improvements in diagnostics and early detection techniques, more cases are now being discovered at an earlier stage, which has raised interest in bone marrow transplantation as a potential treatment or cure. The number of patients who can benefit from transplantation has also increased as a result of the development of targeted therapies and precision medicine techniques, which can be combined with transplants to improve outcomes.

Restraint:

High transplantation costs

The high price of the procedure is one of the main barriers to the market for bone marrow transplants. The evaluation prior to the transplant, the conditioning regimens, the actual transplant, the post-transplant care, and long-term follow-up are all expensive procedures. Many patients may find these costs to be a barrier to care, even in areas with highly developed healthcare systems. Additionally, insurance might not always pay the full cost, leaving patients with sizable financial burdens.

Opportunity:

Modernization of personalized medicine

The field of bone marrow transplantation is greatly impacted by personalized medicine, which is driven by genomic and molecular profiling. Based on a person's genetic and molecular profile, it is possible to improve transplant outcomes and lower complications by customizing transplant strategies and post-transplant therapies. Moreover, this strategy reduces negative effects while improving the general efficacy of transplantation.

Threat:

Healthcare costs and economic constraints

The significant financial burden it places on patients and healthcare systems is one of the main threats to the bone marrow transplant market. Many patients may choose not to undergo transplantation due to the high costs involved, including those of pre-transplant evaluation, conditioning regimens, the actual transplantation, post-transplant care, and long-term follow-up. Additionally, high medical expenses can also put a strain on insurance plans and prevent underserved populations from receiving transplants.

COVID-19 Impact:

On the market for bone marrow transplants, the COVID-19 pandemic had a sizable effect. Worldwide healthcare systems were affected by the pandemic, which included the postponement or cancellation of non-urgent transplant procedures in order to conserve healthcare resources and reduce infection risks for susceptible patients. However, as concerns about transplant recipients Immuno-compromised states increased, strict infection control measures and modifications to transplant protocols became necessary.

The Leukemia segment is expected to be the largest during the forecast period

In the bone marrow transplant market, leukemia holds the largest market share. One of the most common and well-known causes of bone marrow transplantation is leukemia, which is characterized by the abnormal proliferation of white blood cells. The high prevalence of different leukemia types, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML), significantly increases the demand for transplantation services. Moreover, the success rates for leukemia patients have also improved thanks to improvements in transplant methods, supportive care, and targeted therapies, which have further fueled this market's expansion.

The Ambulatory Surgical Centers segment is expected to have the highest CAGR during the forecast period

The bone marrow transplant market's, Ambulatory Surgical Centers (ASCs) segment holds the highest CAGR. ASCs provide a variety of outpatient surgical procedures, including some medical treatments and minimally invasive surgeries. Their growing popularity is a result of their capacity to offer affordable and practical healthcare, shorter hospital stays, and lower infection risks. Additionally, ASCs have diversified their offerings in recent years to include a number of specialties, such as orthopedics, ophthalmology, gastroenterology, and pain management.

Region with largest share:

The North American region holds the largest market share for bone marrow transplants. This dominance can be attributed to a number of things, including a strong regulatory environment, an established healthcare infrastructure, a high prevalence of haematological disorders requiring bone marrow transplants, and cutting-edge medical technologies. Additionally, North America benefits from extensive research and development efforts, significant healthcare expenditures, and a sizable donor pool. The region's market leadership has also been aided by growing patient and healthcare provider awareness of the advantages of bone marrow transplantation.

Region with highest CAGR:

The market for bone marrow transplants has seen the highest CAGR in the Middle East and North Africa (MENA) region. Increased healthcare investments, a growing healthcare infrastructure, and rising public awareness of cutting-edge treatments like bone marrow transplants are a few of the factors driving this growth. Moreover, the United Arab Emirates, Saudi Arabia, and Qatar are among the MENA nations that have made significant improvements to their healthcare infrastructure, enabling their populations to access bone marrow transplantation more easily. The rising demand for transplantation services is also a result of the region's increasing prevalence of haematological disorders, which is fueling the market's expansion.

Key players in the market:

Some of the key players in Bone Marrow Transplant market include: Gamida Cell Ltd., Mesoblast Ltd., American Type Culture Collection (ATCC) Inc, Lonza Group Ltd., FUJIFILM Cellular Dynamics, Inc., ReachBio LLC., Sanofi-Aventis LLC., PromoCell GmbH, Abbott Laboratories Inc, The Emmes Company LLC, CORESTEM, Inc., StemCell Technologies., Hemacare Corporation, AllCells LLC., Lifeline Cell Technology LLC, ReeLabs Pvt. Ltd., Charles River Laboratories and Merck Millipore Corporation .

Key Developments:

In June 2023, Lonza, a trusted partner of the pharmaceutical, biotech, and nutrition industries, has entered into a ten-year Virtual Power Purchase Agreement with IGNIS. A VPPA represents a tailored and adaptable solution that caters to the needs of companies like Lonza, which operates in multiple sites. Unlike traditional power purchase agreements, VPPAs offer more flexibility and attract investments in the solar electricity production facilities as they are not linked to photovoltaic production facilities through physical grids.

In January 2023, FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics' iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.

In October 2020, Gamida Cell Ltd., a leading cellular and immune therapeutics company, and Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, today announced an expansion of their existing strategic collaboration for omidubicel, Gamida Cell's advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell transplant.

Transplant Types Covered:

  • Autologous Bone Marrow Transplant
  • Allogeneic Bone marrow Transplant
  • Other Transplant Types

Disease Indications Covered:

  • Leukemia
  • Lymphoma
  • Myeloma
  • Thalassemia
  • Myelodysplastic Syndrome
  • Myeloproliferative Disorders
  • Aplastic Anemia
  • Solid Tumors
  • Sickle cell Anemia
  • Other Disease Indications

End Users Covered:

  • Hospitals
  • Multispecialty Clinics
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Bone Marrow Transplant Market, By Transplant Type

  • 5.1 Introduction
  • 5.2 Autologous Bone Marrow Transplant
  • 5.3 Allogeneic Bone marrow Transplant
  • 5.4 Other Transplant Types

6 Global Bone Marrow Transplant Market, By Disease Indication

  • 6.1 Introduction
  • 6.2 Leukemia
  • 6.3 Lymphoma
  • 6.4 Myeloma
  • 6.5 Thalassemia
  • 6.6 Myelodysplastic Syndrome
  • 6.7 Myeloproliferative Disorders
  • 6.8 Aplastic Anemia
  • 6.9 Solid Tumors
  • 6.10 Sickle cell Anemia
  • 6.11 Other Disease Indications

7 Global Bone Marrow Transplant Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Multispecialty Clinics
  • 7.4 Ambulatory Surgical Centers
  • 7.5 Other End Users

8 Global Bone Marrow Transplant Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Gamida Cell Ltd.
  • 10.2 Mesoblast Ltd.
  • 10.3 American Type Culture Collection (ATCC) Inc
  • 10.4 Lonza Group Ltd.
  • 10.5 FUJIFILM Cellular Dynamics, Inc.
  • 10.6 ReachBio LLC.
  • 10.7 Sanofi-Aventis LLC.
  • 10.8 PromoCell GmbH
  • 10.9 Abbott Laboratories Inc
  • 10.10 The Emmes Company LLC
  • 10.11 CORESTEM, Inc.
  • 10.12 StemCell Technologies.
  • 10.13 Hemacare Corporation
  • 10.14 AllCells LLC.
  • 10.15 Lifeline Cell Technology LLC
  • 10.16 ReeLabs Pvt. Ltd.
  • 10.17 Charles River Laboratories
  • 10.18 Merck Millipore Corporation

List of Tables

  • Table 1 Global Bone Marrow Transplant Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 3 Global Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 4 Global Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 5 Global Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 6 Global Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 7 Global Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 8 Global Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 9 Global Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 10 Global Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 11 Global Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 12 Global Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 13 Global Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 14 Global Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 15 Global Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 16 Global Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 17 Global Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 18 Global Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 19 Global Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 20 Global Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 21 Global Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 22 North America Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 24 North America Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 25 North America Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 26 North America Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 27 North America Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 28 North America Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 29 North America Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 30 North America Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 31 North America Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 32 North America Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 33 North America Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 34 North America Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 35 North America Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 36 North America Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 37 North America Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 38 North America Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 39 North America Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 40 North America Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 41 North America Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 42 North America Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Europe Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 45 Europe Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 46 Europe Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 47 Europe Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 48 Europe Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 49 Europe Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 50 Europe Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 51 Europe Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 52 Europe Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 53 Europe Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 54 Europe Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 55 Europe Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 56 Europe Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 57 Europe Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 58 Europe Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 59 Europe Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 60 Europe Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 61 Europe Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 62 Europe Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 63 Europe Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 64 Asia Pacific Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 66 Asia Pacific Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 67 Asia Pacific Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 68 Asia Pacific Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 69 Asia Pacific Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 70 Asia Pacific Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 71 Asia Pacific Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 72 Asia Pacific Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 73 Asia Pacific Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 74 Asia Pacific Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 75 Asia Pacific Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 76 Asia Pacific Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 77 Asia Pacific Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 78 Asia Pacific Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 79 Asia Pacific Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 80 Asia Pacific Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 81 Asia Pacific Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 82 Asia Pacific Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 83 Asia Pacific Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 84 Asia Pacific Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 85 South America Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 87 South America Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 88 South America Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 89 South America Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 90 South America Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 91 South America Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 92 South America Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 93 South America Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 94 South America Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 95 South America Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 96 South America Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 97 South America Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 98 South America Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 99 South America Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 100 South America Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 101 South America Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 102 South America Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 103 South America Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 104 South America Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 105 South America Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 106 Middle East & Africa Bone Marrow Transplant Market Outlook, By Country (2021-2030) ($MN)
  • Table 107 Middle East & Africa Bone Marrow Transplant Market Outlook, By Transplant Type (2021-2030) ($MN)
  • Table 108 Middle East & Africa Bone Marrow Transplant Market Outlook, By Autologous Bone Marrow Transplant (2021-2030) ($MN)
  • Table 109 Middle East & Africa Bone Marrow Transplant Market Outlook, By Allogeneic Bone marrow Transplant (2021-2030) ($MN)
  • Table 110 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other Transplant Types (2021-2030) ($MN)
  • Table 111 Middle East & Africa Bone Marrow Transplant Market Outlook, By Disease Indication (2021-2030) ($MN)
  • Table 112 Middle East & Africa Bone Marrow Transplant Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 113 Middle East & Africa Bone Marrow Transplant Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 114 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myeloma (2021-2030) ($MN)
  • Table 115 Middle East & Africa Bone Marrow Transplant Market Outlook, By Thalassemia (2021-2030) ($MN)
  • Table 116 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myelodysplastic Syndrome (2021-2030) ($MN)
  • Table 117 Middle East & Africa Bone Marrow Transplant Market Outlook, By Myeloproliferative Disorders (2021-2030) ($MN)
  • Table 118 Middle East & Africa Bone Marrow Transplant Market Outlook, By Aplastic Anemia (2021-2030) ($MN)
  • Table 119 Middle East & Africa Bone Marrow Transplant Market Outlook, By Solid Tumors (2021-2030) ($MN)
  • Table 120 Middle East & Africa Bone Marrow Transplant Market Outlook, By Sickle cell Anemia (2021-2030) ($MN)
  • Table 121 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other Disease Indications (2021-2030) ($MN)
  • Table 122 Middle East & Africa Bone Marrow Transplant Market Outlook, By End User (2021-2030) ($MN)
  • Table 123 Middle East & Africa Bone Marrow Transplant Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 124 Middle East & Africa Bone Marrow Transplant Market Outlook, By Multispecialty Clinics (2021-2030) ($MN)
  • Table 125 Middle East & Africa Bone Marrow Transplant Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 126 Middle East & Africa Bone Marrow Transplant Market Outlook, By Other End Users (2021-2030) ($MN)